|
KaloBios Pharma pulls plug on asthma drug, shares plunge
Reuters (Reuters) – Shares of KaloBios Pharmaceuticals Inc fell nearly 50 percent in extended trade after the company said it would stop developing an asthma drug that failed in a mid-stage study. The drug, KB003, failed to bring about a clinically meaningful … KaloBios stock slides; to stop asthma study KaloBios: KB003 Fails To Meet Primary Goal In Phase 2 Asthma Study |
View full post on asthma – Google News